AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. 詳細を表示
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today...
Cash, cash equivalents, and investments of $104.5 million at June 30, 2024; cash runway anticipated to fund operations through 2027 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical...
EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with MAC lung disease AN2 plans to shift focus to internal boron...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.02 | -1.88679245283 | 1.06 | 1.09 | 1.0313 | 130290 | 1.05883096 | CS |
4 | 0 | 0 | 1.04 | 1.09 | 1.01 | 230072 | 1.04580161 | CS |
12 | -1.56 | -60 | 2.6 | 3.07 | 0.87 | 624227 | 1.16191934 | CS |
26 | -2.37 | -69.5014662757 | 3.41 | 3.535 | 0.87 | 399304 | 1.54746277 | CS |
52 | -14.42 | -93.2729624838 | 15.46 | 22.22 | 0.87 | 323499 | 3.67922639 | CS |
156 | -15.81 | -93.8278931751 | 16.85 | 23.58 | 0.87 | 166292 | 5.4573238 | CS |
260 | -15.81 | -93.8278931751 | 16.85 | 23.58 | 0.87 | 166292 | 5.4573238 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約